INTRODUCING NOBIVAC® EDGE® VACCINES

Choose the best protection for your clients with convenient small dose options that deliver powerful protection for dogs of all sizes.

The first and only 0.5 mL leptospirosis vaccine shown to be effective against disease, mortality and shedding for dogs of all sizes.

  • Shown to be effective against disease, mortality, and leptospiruria caused by four Leptospira serovars:2,5
    • L. canicola
    • L. icterohaemorrhagiae
    • L. pomona
    • L. grippotyphosa

  • A porous filtration membrane selectively removes extraneous proteins, salts, and solvents
  • Fewer total proteins (TP) means a more purified final product, which may reduce unwanted immune system responses such as vaccine reactions1
  • Promotes a higher level of vaccine quality
  • Same process used for Nobivac® Lepto4, Nobivac® Canine-1 DAPPv+L4, and Nobivac® EDGE®Lepto4

The only 0.5 mL that provides protection against parainfluenza, distemper, adenovirus type 1 (hepatitis), and parvovirus in one formula.

  • The only 0.5 mL combination vaccine formula to include parainfluenza
  • Protects against all known strains of canine parvovirus (CPV), including CPV-2c3,4
  • Contains CPV-2b, one of the most prevalent field strains of parvovirus
  • High antigenic mass (titer), low passage parvovirus vaccine
  • Overrides CPV maternal antibodies in young puppies1
  • Protects against adenovirus type 1 that causes hepatitis in dogs
  • Systemic administration stimulates a strong IgG response (CPiV)1

  • Lower total protein level than other 0.5 ml vaccine options1
  • Onderstepoort-type strain in Nobivac® vaccines provides a high level of safety (CDV)1

The only 0.5 mL combo vaccine to provide parainfluenza protection in combination with four-way leptospirosis protection.

  • The only 0.5 mL leptospirosis vaccine to aid in the prevention of disease, mortality, and leptospiriuria caused by four Leptospira serovars2,5
  • The only 0.5 mL combination vaccine formula to include parainfluenza
  • Protects against all known strains of canine parvovirus (CPV), including CPV-2c3,4
  • Contains CPV-2b, one of the most prevalent field strains of parvovirus
  • High antigenic mass (titer), low passage parvovirus vaccine
  • Overrides CPV maternal antibodies in young puppies1
  • Systemic administration stimulates a strong IgG response (CPiV)1
  • Protects against adenovirus type 1 that causes hepatitis in dogs

  • 99% Reaction Free: out of 1,583 doses given in Clinical Impressions study1
  • Lower total protein level than other 0.5 ml vaccine options1
  • Onderstepoort-type strain in Nobivac® vaccines provides a high level of safety (CDV)1

  • A porous filtration membrane selectively removes extraneous proteins, salts, and solvents
  • Fewer total proteins (TP) means a more purified final product, which may reduce unwanted immune system responses such as vaccine reactions1
  • Promotes a higher level of vaccine quality
  • Same process used for Nobivac® Lepto4, Nobivac® Canine-1 DAPPv+L4, and Nobivac® EDGE® Lepto4

GET NOBIVAC® EDGE® FULL SIZE PROTECTION, HALF SIZE VACCINES

Get the proven efficacy of Nobivac® EDGE® 0.5 mL for dogs of all sizes.

For technical assistance or to report a suspected adverse drug reaction, contact Merck Animal Health at 1-800-224-5318